The Phase 2 ZEN-3694 TNBC trial with Pfizer's PARP inhibitor Talazoparib is now listed on ClinicalTrials.gov as record NCT03901469

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

Official Title: A Phase 2 Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer

Estimated Study Start Date:  April 2019

Estimated Primary Completion Date:  September 2020

Estimated Study Completion Date:  January 2021

Experimental: ZEN003694 in Combination with Talazoparib

ZEN003694 will be administered orally once daily with Talazoparib orally once daily in 28-day cycles, enrolling TNBC patients. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2

Brief Summary:

This is two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is dose escalation and Part 2 is a Simon 2-Stage design